Interim Report 2026
Filed with HKEX · Stock code 2186 · · 69 pages · English
Summary by 6ix AI
The report highlights a decrease in revenue and gross profit compared to the previous year, while net profit and profit attributable to shareholders have increased. The company continues to focus on innovation in drug development, particularly in oncology and CNS therapeutic areas, with a robust pipeline of products. Luye Pharma operates globally, with a significant presence in major pharmaceutical markets and a commitment to expanding its research and development capabilities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Luye Pharma
- Luye Pharma Announces 2026 Interim Results
- Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R...
- Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
- Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
- First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating...
Later from Luye Pharma
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement renewed inclusion of the group's innovative antidepressant Ruoxinlin in China's 2026 national reimbursement drug list
- Voluntary announcement approval obtained for the group's innovative drug LY03021 for clinical trials in the U.S.
- Voluntary announcement approval of the group's innovative drug Ruoxinlin in China for the new indication of generalized anxiety disorder
Follow Luye Pharma into a list and get an email when it puts out news.
Follow Luye Pharma